dNP2 is a blood–brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis-Reference-Cited by-同舟云学术

dNP2 is a blood–brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis

Published:2015-09-15 Issue:1 Volume:6 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Lim Sangho,Kim Won-Ju,Kim Yeon-Ho,Lee Sohee,Koo Ja-Hyun,Lee Jung-Ah,Yoon Heeseok,Kim Do-Hyun,Park Hong-Jai,Kim Hye-Mi,Lee Hong-Gyun,Yun Kim Ji,Lee Jae-Ung,Hun Shin Jae,Kyun Kim Lark,Doh Junsang,Kim Hongtae,Lee Sang-Kyou,Bothwell Alfred L. M.,Suh Minah,Choi Je-Min

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms9244.pdf

Reference70 articles.

1. Trapp, B. D., Ransohoff, R. & Rudick, R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 12, 295–302 (1999).

2. Rangachari, M. & Kuchroo, V. K. Using EAE to better understand principles of immune function and autoimmune pathology. J. Autoimmun. 45, 31–39 (2013).

3. Goverman, J. Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 9, 393–407 (2009).

4. Pierson, E., Simmons, S. B., Castelli, L. & Goverman, J. M. Mechanisms regulating regional localization of inflammation during CNS autoimmunity. Immunol. Rev. 248, 205–215 (2012).

5. Wingerchuk, D. M. & Carter, J. L. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin. Proc. 89, 225–240 (2014).

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies for organic nanoparticles delivering CRISPR/Cas9 for cancer therapy: Challenges and breakthroughs;Materials & Design;2024-08

2. Molecular determinants for brain targeting by peptides: a meta-analysis approach with experimental validation;Fluids and Barriers of the CNS;2024-05-27

3. The Application of Nanovaccines in Autoimmune Diseases;International Journal of Nanomedicine;2024-01

4. TRAF6 signaling in T cells is crucial for the pathogenicity of experimental autoimmune encephalomyelitis;International Immunology;2023-12-28

5. Brain-Penetrating Peptide Shuttles across the Blood–Brain Barrier and Extracellular-like Space;Bioconjugate Chemistry;2023-12-12